OX40 | NCT02528357 | GSK3174998 alone or with pembrolizumab | Advanced solid tumor | 1 |
NCT02737475 | BMS-986178 alone or in combination With nivolumab and/or Ipilimumab | Advanced solid tumor | 1/2 |
NCT03092856 | Axitinib With or Without PF-04518600 | Metastatic kidney cancer | 2 |
NCT04198766 | INBRX-106 (Hexavalent OX40 Agonist) and pembrolizumab | Locally advanced or metastatic solid tumor | 1 |
NCT03831295 | SD-101 and BMS-986178 | Locally advanced or metastatic solid tumor | 1 |
NCT03894618 | SL-279252 (PD1-Fc- OX40L) | Locally advanced or metastatic solid tumor or lymphoma | 1 |
NCT03971409 | Avelumab with binimetinib, utomilumab or PF-04518600 | Stage IV or unresectable or recurrent triple negative breast cancer | 1 |
NCT03217747 | Avelumab, utomilumab, PF-04518600 and radiation therapy | Advanced solid tumor | 1/2 |
NCT03782467 | ATOR-1015 (Bispecific human monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and OX40) | Advanced solid tumor | 1 |
NCT03447314 | Combination of GSK1795091 and Immunotherapies (GSK1795091Drug: GSK3174998Drug: GSK3359609Drug: pembrolizumab) | Advanced solid tumor | 1 |
4-1BB | NCT02845323 | Neoadjuvant nivolumab with and without urelumab | Cisplatin ineligible or chemorefractory muscle invasive urothelial carcinoma | 2 |
NCT03364348 | 4-1BB agonist monoclonal antibody PF-05082566 with trastuzumab emtansine or trastuzumab | Advanced HER2-positive breast cancer | 1 |
NCT03217747 | Avelumab, utomilumab, PF-04518600 (Anti OX40) and radiation therapy | Advanced solid tumor | 1/2 |
NCT04009460 | ES101 (PD-L1×4–1 BB bispecific antibody) | Advanced solid tumor | 1 |
NCT03650348 | PRS-343 in combination with atezolizumab | HER2-positive solid tumor | 1 |
NCT04144842 | ATOR-1017 | Advanced solid tumor | 1 |
NCT04121676 | AGEN2373 | Advanced cancer | 1 |
NCT03881488 | CTX-471 post-PD-1/PD-L1 | Locally advanced solid tumor/metastatic cancer | 1 |
GITR | NCT02598960 | BMS-986156 alone or in combination with nivolumab | Advanced solid tumor | 1/2 |
NCT04021043 | MS-986156, Ipilimumab, and nivolumab with or without stereotactic body radiation therapy | Advanced or metastatic lung/chest or liver cancer | 1/2 |
NCT03799003 | ASP1951 with or without pembrolizumab | Advanced solid tumor | 1 |
NCT03123783 | APX005M in combination with nivolumab | Non-small cell lung cancer and melanoma | 1 |
NCT02740270 | GWN323 alone and in combination with PDR001 | Advanced malignancies and lymphomas | 1 |
NCT03126110 | INCAGN01876 combined with immune therapies | Locally advanced solid tumor/metastatic cancer | 1/2 |
CD40 | NCT03123783 | APX055M in combination with nivolumab | Non-small cell lung cancer/metastatic melanoma | 1/2 |
NCT02706353 | APX005M in combination with pembrolizumab | Metastatic melanoma | 1/2 |
NCT02376699 | SEA-CD40 | Advanced malignancy | 1 |
NCT03852511 | NG-350A oncolytic virus | Metastatic cancer | 1 |
NCT02705196 | LOAd704 oncolytic virus | Pancreatic cancer | 1/2 |
NCT03329950 | CDX-1140 as monotherapy or in combination | Advanced malignancies | 1 |
ICOS | NCT03989362 | Vopratelimab (JTX-2011) and a CTLA-4 inhibitor | Non-small cell lung cancer/urothelial cancer | 2 |
NCT03219224 | Vopratelimab alone and in combination with anti-PD-1 or anti-CTLA-4 | Advanced solid tumor | 1/2 |
NCT03829501 | KY1044 and atezolizumab | Advanced cancer | 1/2 |
NCT02723955 | GSK3359609 | Advanced solid tumor | 1 |
NCT03693612 | GSK3359609 plus tremelimumab | Advanced solid tumor | 2 |